Key result
Rocuronium speeds onset of action ~40% vs cisatracurium, yielding better intubating conditions.
Why the study?
The search for an optimum neuromuscular blocking drug with appropriate intubating circumstances is continuous, prompting a comparison of rocuronium and cisatracurium at twice the ED95 dose during abdominal surgery.
Does rocuronium improve onset of action, intubating conditions, and recovery compared to cisatracurium in adult patients undergoing abdominal surgery?
RCT (n=60)
Double-blind
Block randomization with a sealed envelope system
No
Does rocuronium improve onset of action, intubating conditions, and recovery compared to cisatracurium in adult patients undergoing abdominal surgery?
Absolute Event Rate: 2.4% vs 4%
p-value: p=0.000
Rocuronium provides faster onset, better intubating conditions, and quicker recovery than cisatracurium for patients undergoing abdominal surgery.
Rocuronium may be favored for faster intubation in abdominal surgery; extends RCT evidence favoring it over cisatracurium for onset and recovery.
Background: Neuromuscular blocking drugs (NMBD) have paved the way for the conduct of every known surgical procedure. However, the hunt for optimum NMD with appropriate intubating circumstances is continuous. Rocuronium and cisatracurium are amongst the newer NMBDs. We aim to compare the onset of action, intubating conditions, duration of action, and recovery features in a dose twice the ED95 in patients having abdominal surgery. Methods: A total 60 American Society of Anesthesiology (ASA) I and II adult patients were randomized equally into Group A and Group B. Group A received Inj. Rocuronium 0.6 mg/kg and Group B received Inj. Cisatracurium 0.10 mg/kg. We assessed the intubating conditions after ensuring jaw relaxation using both the clinical criteria and neuromuscular monitoring whereas onset time, duration of action and recovery time were assessed using neuromuscular monitoring only. Results: In Group A, a significant rapid onset of action of muscle relaxant was seen compared to Group B (2.4±0.30 mins versus 4.0±0.09 mins, p= 0.00). 93% patients had excellent intubating conditions in Group A compared to 73% patients in Group B (p= 0.038). The duration of action in Group A was 36.73±1.05 mins and in Group B was 47.40 ±1.33mins (p=0.00). Similarly, early mean duration of recovery was found in Group A-45.30±1.29mins versus Group B -57.77±1.19 mins, p= 0.00). Conclusion: Rocuronium provides rapid onset of action with excellent intubating conditions, and shorter duration of action with an early recovery time compared to cisatracurium.
No takes yet. Share an insight, caveat, or question.
Taneja et al. (2023) conducted an RCT in Abdominal surgery under general anesthesia (n=60). Rocuronium vs. Cisatracurium 0.10 mg/kg was evaluated on Onset of action (minutes) (p=0.000). Rocuronium provided a significantly more rapid onset of action (2.4 vs 4.0 minutes, p=0.000) and a higher rate of excellent intubating conditions (93% vs 73%) compared to cisatracurium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: